- You can view the full Pfizer Ratings Report.
- Use our drugs section to find industry-relevant news.
- Or find some new ideas from our top rated stocks lists.
- Find other investment ideas from our top rated ETFs lists.
Pfizer is working on its eighth straight loss after failing near heavy resistance.
Shares of Pfizer have been on the decline, losing some 5% from its January 5 high of $33.61 a share.
CoLucid will be acquired for $46.50 per share, a 33% premium to the stock's closing price Tuesday.
The $101 billion market cap pharma could be put in play or targeted by an activist investor soon.